Ian Mortimer
CEO, CFO at Xenon Pharmaceuticals Inc. (XENE); CEO, President at Xenon Pharmaceuticals Inc. (XENE)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 1SEC | XENEXenon Pharmaceuticals Inc. | Buy | 30,00049,923 held (+151%) | $37.38 | $1.1M | -2.5% |
| Mar 13SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 7,30819,923 held (−27%) | $55.23 | $404K | -34.0% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 21,79159,209 held (−27%) | $58.81 | $1.3M | -38.0% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 31,69427,515 held (−54%) | $59.88 | $1.9M | -39.1% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 21,5156,000 held (−78%) | $60.49 | $1.3M | -39.8% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 12,47918,521 held (−40%) | $59.50 | $743K | -38.8% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 10,0728,449 held (−54%) | $60.47 | $609K | -39.7% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 2,4496,000 held (−29%) | $61.26 | $150K | -40.5% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 43,34872,652 held (−37%) | $59.26 | $2.6M | -38.5% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 61,6526,000 held (−91%) | $60.08 | $3.7M | -39.3% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 65,0006,000 held (−92%) | $62.06 | $4.0M | -41.3% |
| Mar 11SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 11,26914,731 held (−43%) | $60.11 | $677K | -39.4% |
| Jan 2SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 37,9388,062 held (−82%) | $44.40 | $1.7M | -17.9% |
| Jan 2SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 2,0626,000 held (−26%) | $44.93 | $93K | -18.9% |
| Dec 9SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 14,37516,830 held (−46%) | $45.03 | $647K | -19.1% |
| Dec 9SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 8,8208,010 held (−52%) | $45.59 | $402K | -20.1% |
| Dec 9SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 2,0106,000 held (−25%) | $46.32 | $93K | -21.3% |
| Dec 3SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 9731,205 held (−0%) | $45.01 | $4K | -19.0% |
| Oct 1SEC | XENEXenon Pharmaceuticals Inc. | Sell Plan | 25,00031,302 held (−44%) | $40.16 | $1.0M | -9.3% |
- Buy
CEO, President Ian Mortimer bought $1.1M of XENE at $37.38 — first open-market purchase in our records; raises the stake by 151%.
- Sell
CEO, President Ian Mortimer sold $404K of XENE at $55.23 — cuts the stake by 27%; pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Ian Mortimer sold $1.3M of XENE at $58.81 — cuts the stake by 27%; pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Ian Mortimer sold $1.9M of XENE at $59.88 — cuts the stake by 54%; pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Ian Mortimer sold $1.3M of XENE at $60.49 — cuts the stake by 78%; pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Ian Mortimer sold $743K of XENE at $59.50 — cuts the stake by 40%; pre-scheduled 10b5-1 plan sale.